Women with endometriosis face a frustrating reality: conventional treatments often fail to adequately control their debilitating pelvic pain while introducing unwanted side effects. This gap has driven many to seek alternatives, with cannabis emerging as a potential therapeutic option that could reshape pain management for this underserved population.
New Zealand researchers tracked 18 women with endometriosis who received prescribed medical cannabis over 12 weeks, documenting substantial pain reductions and quality of life improvements. Overall pelvic pain scores dropped from 5.46 to 3.77 on a 10-point scale—a 31% decrease. Most dramatically, worst pain episodes fell from 7.62 to 5.38, representing a meaningful shift from severe to moderate pain levels. Quality of life measures using the standardized EHP-30 assessment showed even more pronounced benefits, with scores improving from 68.77 to 37.40—nearly a 46% enhancement. Participants used either CBD oil alone or combined with dried cannabis flower, with minimal adverse effects reported.
This cohort study adds to mounting evidence that cannabis-based medicines may offer genuine relief for endometriosis sufferers, though significant limitations remain. The small sample size and observational design prevent definitive conclusions about causation. Without a control group, placebo effects cannot be ruled out, and the three-month timeframe offers no insight into long-term efficacy or safety. Most critically, endometriosis research has historically suffered from inadequate funding and attention, leaving patients with few evidence-based alternatives to explore. While these results appear promising and align with patient testimonials, larger randomized controlled trials remain essential to establish cannabis as a legitimate therapeutic option rather than simply documenting patient experiences with an increasingly accessible treatment.